The ADDC and AstraZeneca are pleased to announce the third annual call for proposals from the AZ-ADDC partnership. The RFP application deadline is October 31st, 2016. 

Click here for the RFP.

The Academic Drug Discovery Consortium (ADDC) and AstraZeneca are seeking applications from ADDC members who are interested in high quality screening compounds provided by AstraZeneca. Proposals can select from a 250,000 diversity set, a 13,000 annotated set covering 1200 human targets, or a low molecular weight fragment screening set of 17,000 compounds. AstraZeneca offers support of up to $40k to help with the screen.

Proposals are being sought in the following areas:

• Cardiovascular & Metabolic Disease (CVMD)
• Respiratory, Inflammation, & Autoimmune (R&A)
• Oncology
• Neuroscience